Vis enkel innførsel

dc.contributor.authorDhar, Indu
dc.contributor.authorSvingen, Gard Frodahl Tveitevåg
dc.contributor.authorPedersen, Eva Ringdal
dc.contributor.authorUlvik, Arve
dc.contributor.authorBjørnestad, Espen Øglænd
dc.contributor.authorDankel, Simon N
dc.contributor.authorMellgren, Gunnar
dc.contributor.authorNygård, Ottar Kjell
dc.date.accessioned2023-01-11T10:04:52Z
dc.date.available2023-01-11T10:04:52Z
dc.date.created2022-10-30T07:05:42Z
dc.date.issued2022
dc.identifier.issn2772-4875
dc.identifier.urihttps://hdl.handle.net/11250/3042625
dc.description.abstractBackground Physical activity (PA) influences sympathetic stimulation, platelet activation as well as vascular function, and has been associated with improved health outcomes in patients with coronary heart disease. β-blocker therapy reduces sympathetic activity and improves platelet and endothelial function. We investigated if β-blocker treatment modifies the association of self-reported PA with the risk of all-cause mortality. Methods A total of 2284 patients undergoing elective coronary angiography for suspected stable angina pectoris (SAP) were studied. Using Cox modeling, we examined associations between PA (categorized as ‘sedentary/inactive’, ‘low’, ‘moderate’, and ‘high’) and all-cause mortality according to β-blocker therapy. Results During a median follow-up of 10.3 years, 390 patients (17.1%) died. Higher PA was generally associated with a more favorable cardiovascular risk profile. Compared to the patients who were sedentary or inactive, the age and sex adjusted HRs (95% CI) for all-cause mortality were 0.89 (0.66–1.20), 0.73 (0.57–0.95) and 0.72 (0.55–0.95) in the low, moderate and high PA group, respectively. However, and notably, these risk estimates were 0.85 (0.60–1.20), 0.65 (0.47–0.89) and 0.58 (0.41–0.81) in β-blocker treated subjects vs. 1.00 (0.57–1.78), 0.96 (0.61–1.52) and 1.20 (0.74–1.95) in non-treated groups (Pinteraction = 0.018). The results were essentially similar in the multivariable adjusted models. Conclusions In patients with suspected SAP, increased PA was associated with reduced mortality risk primarily in patients treated with β-blockers.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titlePhysical activity and risk of all-cause mortality in patients with stable angina pectoris: Effect modification by β-blocker treatmenten_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumber200150en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.ijcrp.2022.200150
dc.identifier.cristin2066406
dc.source.journalInternational Journal of Cardiology: Cardiovascular Risk and Prevention (IJCCRP)en_US
dc.identifier.citationInternational Journal of Cardiology: Cardiovascular Risk and Prevention (IJCCRP). 2022, 15, 200150.en_US
dc.source.volume15en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal